Angiotensin-converting enzyme inhibiting drugs, currently used to treat high blood pressure, may also be useful in weight loss and the prevention of diabetes, according to a study by the Australian Howard Florey Institute.
The study, published in the Proceedings of the National Academy of Sciences, found ACE-deficient mice weighed 20% less and had 50%-60% less body fat than normal mice, despite being no more active, indicating a higher metabolism. Later experiments showed the mice retained an increased metabolic rate as they matured.
ACE inhibitors and angiotensin-receptor blockers are already widely used to treat hypertension, suggesting the drugs as a potential candidate for a new weight-loss treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze